High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.

PURPOSE We report the results of intensive chemotherapy with high-dose melphalan (HDM) following conventional-dose cytoreductive chemotherapy in previously untreated patients with myeloma. PATIENTS AND METHODS From 1986 to 1991, 53 previously untreated patients with myeloma received HDM 200 mg/m2 plus methylprednisolone 1.5 g daily (MP) for 5 days with autologous bone marrow transplantation (ABMT) after cytoreductive chemotherapy. RESULTS At the time of HDM administration, responses to induction therapy were complete remission (CR) in nine patients, partial remission (PR) in 38, and no response (NR) in six. Following HDM, all but one patient responded, with 40 patients achieving a CR (75%). There was one treatment-related death following HDM. The median time to reach a WBC count more than 1,000/microL and platelet count more than 25,000/microL was 19 days (range, 13 to 30) and 24 days (range, 15 to 55), respectively. The median duration of response has not been reached at 20 months, and it is significantly longer for patients in CR than for those in PR (P < .025). Currently, with a median follow-up duration of 31 months (range, 6 to 58), 12 patients are dead and 40 are alive, and the estimated probability of survival at 54 months is 63%. Multivariate analysis found hemoglobin (Hb) more than 10 g/dL (P = .012), and stage A disease (P = .001) at diagnosis to be favorable indicators for survival. CONCLUSION Myeloma patients who are able to receive HDM plus ABMT following conventional chemotherapy achieve a high proportion of CRs, which may be associated with prolonged survival.

[1]  M. Gore,et al.  High-dose melphalan for multiple myeloma: long-term follow-up data. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Gore,et al.  Repeat administration of high dose melphalan in relapsed myeloma. , 1993, British Journal of Cancer.

[3]  A. Freedman,et al.  Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. , 1993, Blood.

[4]  B. Mazières,et al.  Maintenance treatment with recombinant alpha interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional induction chemotherapy. , 1991, Bone marrow transplantation.

[5]  J. Trent,et al.  Development and characterization of a melphalan-resistant human multiple myeloma cell line. , 1991, Cancer research.

[6]  B. Barlogie,et al.  Bone marrow transplantation in multiple myeloma. , 1991, Bone marrow transplantation.

[7]  B. Barlogie,et al.  Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors , 1990 .

[8]  D. Cunningham,et al.  Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone , 1990, Hematological oncology.

[9]  B. Barlogie,et al.  High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. , 1990, Blood.

[10]  F. Mandelli,et al.  Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. , 1990, The New England journal of medicine.

[11]  M. Gore,et al.  In vitro studies of ways to overcome resistance to VAMP‐high dose melphalan in the treatment of multiple myeloma , 1989, British journal of haematology.

[12]  D. Bergsagel Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma? , 1989, European journal of cancer & clinical oncology.

[13]  Y. Lévy,et al.  Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. , 1989, Blood.

[14]  B. Barlogie,et al.  Prognostic factors with high-dose melphalan for refractory multiple myeloma [see comments] , 1988 .

[15]  D. Bergsagel Chemotherapy of myeloma: Drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma , 1988, Hematological oncology.

[16]  M. Slevin,et al.  Multiple myeloma treated with high dose intravenous melphalan , 1987, British journal of haematology.

[17]  J. Sporn,et al.  Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. , 1986, Seminars in Oncology.

[18]  T. Mcelwain,et al.  HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA , 1983, The Lancet.

[19]  E. Gehan,et al.  Prognostic factors in multiple myeloma , 1975, Cancer.

[20]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[21]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .